FR21C1051I2 - Nouveau sel hydrogenosulfate - Google Patents
Nouveau sel hydrogenosulfateInfo
- Publication number
- FR21C1051I2 FR21C1051I2 FR21C1051C FR21C1051C FR21C1051I2 FR 21C1051 I2 FR21C1051 I2 FR 21C1051I2 FR 21C1051 C FR21C1051 C FR 21C1051C FR 21C1051 C FR21C1051 C FR 21C1051C FR 21C1051 I2 FR21C1051 I2 FR 21C1051I2
- Authority
- FR
- France
- Prior art keywords
- hydrogenosulfate
- salt
- new
- new hydrogenosulfate
- hydrogenosulfate salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75278105P | 2005-12-21 | 2005-12-21 | |
PCT/US2006/061895 WO2007076245A2 (fr) | 2005-12-21 | 2006-12-12 | Nouveau sel hydrogenosulfate |
Publications (2)
Publication Number | Publication Date |
---|---|
FR21C1051I1 FR21C1051I1 (fr) | 2021-12-24 |
FR21C1051I2 true FR21C1051I2 (fr) | 2023-02-17 |
Family
ID=38218759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR21C1051C Active FR21C1051I2 (fr) | 2005-12-21 | 2021-11-05 | Nouveau sel hydrogenosulfate |
Country Status (31)
Country | Link |
---|---|
US (4) | US20100016393A1 (fr) |
EP (1) | EP1968948B1 (fr) |
JP (1) | JP5127723B2 (fr) |
KR (1) | KR101361460B1 (fr) |
CN (2) | CN102329270A (fr) |
AR (1) | AR058696A1 (fr) |
AU (1) | AU2006330759B2 (fr) |
BR (1) | BRPI0620091A2 (fr) |
CA (1) | CA2634149C (fr) |
CY (1) | CY1114303T1 (fr) |
DK (1) | DK1968948T3 (fr) |
EC (1) | ECSP088597A (fr) |
ES (1) | ES2421746T3 (fr) |
FR (1) | FR21C1051I2 (fr) |
HK (1) | HK1124043A1 (fr) |
HR (1) | HRP20130663T1 (fr) |
HU (1) | HUS2100046I1 (fr) |
IL (1) | IL192224A (fr) |
LT (1) | LTC1968948I2 (fr) |
MX (1) | MX2008008298A (fr) |
MY (1) | MY157733A (fr) |
NL (1) | NL301139I2 (fr) |
NZ (1) | NZ569792A (fr) |
PL (1) | PL1968948T3 (fr) |
PT (1) | PT1968948E (fr) |
RS (1) | RS52843B (fr) |
SI (1) | SI1968948T1 (fr) |
TW (1) | TWI405756B (fr) |
UA (1) | UA93531C2 (fr) |
WO (1) | WO2007076245A2 (fr) |
ZA (1) | ZA200805705B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2130536B1 (fr) | 2002-03-13 | 2013-05-08 | Array Biopharma, Inc. | Dérivés de benzimidazole d'alkylat N3 en tant qu'inhibiteurs de Mek |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
JP2011506420A (ja) * | 2007-12-12 | 2011-03-03 | アストラゼネカ アクチボラグ | Mek阻害剤及びオーロラキナーゼ阻害剤188を含んでなる組合せ |
SA109300195B1 (ar) * | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
WO2011095807A1 (fr) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinaisons d'inhibiteurs de mek et de hh |
WO2012145503A1 (fr) * | 2011-04-21 | 2012-10-26 | Novartis Ag | Combinaisons pharmaceutiques |
EP3608340A1 (fr) | 2011-11-23 | 2020-02-12 | Medlmmune, LLC | Molécules de liaison propres à her3 et utilisation de celles-ci |
WO2013109142A1 (fr) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie |
PL3702351T3 (pl) * | 2012-10-19 | 2024-04-02 | Array Biopharma, Inc. | Formulacja zawierająca inhibitor mek |
ES2642201T3 (es) | 2013-03-06 | 2017-11-15 | Astrazeneca Ab | Inhibidores de quinazolina de formas mutantes de activación del receptor del factor de crecimiento epidérmico |
WO2015041534A1 (fr) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk en combinaison avec raf/erk/mek |
US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (fr) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions pour le traitement du cancer |
CN105566327A (zh) * | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
EP3355923B1 (fr) | 2015-10-01 | 2022-02-23 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Inhibiteurs de l'histone désacétylase utilisables dans le traitement d'un mélanome résistant aux médicaments |
US9844540B2 (en) | 2015-10-06 | 2017-12-19 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
WO2017099591A1 (fr) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Traitement de cancers à mutation braf résistants aux inhibiteurs |
WO2017204626A1 (fr) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Polythérapie combinant map2k4/map3k1 et une inhibition de mek/erk |
EP3712133A4 (fr) * | 2017-11-14 | 2021-05-12 | Shenzhen TargetRx, Inc. | Composé de benzimidazole substitué et composition le comprenant |
TWI791916B (zh) * | 2018-10-31 | 2023-02-11 | 法商施維雅藥廠 | Bcl-2抑制劑的新穎鹽、相關的結晶形式、其製備方法及包含其之醫藥組合物 |
US20220405506A1 (en) * | 2021-06-22 | 2022-12-22 | Intrinsic Innovation Llc | Systems and methods for a vision guided end effector |
WO2023238000A1 (fr) * | 2022-06-06 | 2023-12-14 | Glenmark Life Sciences Limited | Procédé de préparation de sélumétinib et de sels de celui-ci |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (fr) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf |
DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
EP2130536B1 (fr) * | 2002-03-13 | 2013-05-08 | Array Biopharma, Inc. | Dérivés de benzimidazole d'alkylat N3 en tant qu'inhibiteurs de Mek |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
EP1913942B1 (fr) | 2003-09-09 | 2009-11-11 | Biogen Idec International GmbH | Utilisation de dérivés de l'acide fumarique pour l'inibition de l'incorporation de la thymidine provoquee par le PDGF par les cellules musculaires lisses des bronches et pour l'inhibition de la prolifération des cellules musculaires lisses des broches |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
SA109300195B1 (ar) * | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
-
2006
- 2006-12-04 TW TW095144927A patent/TWI405756B/zh active
- 2006-12-12 UA UAA200808839A patent/UA93531C2/ru unknown
- 2006-12-12 WO PCT/US2006/061895 patent/WO2007076245A2/fr active Application Filing
- 2006-12-12 MX MX2008008298A patent/MX2008008298A/es active IP Right Grant
- 2006-12-12 DK DK06840192.6T patent/DK1968948T3/da active
- 2006-12-12 US US12/097,942 patent/US20100016393A1/en not_active Abandoned
- 2006-12-12 RS RS20130295A patent/RS52843B/en unknown
- 2006-12-12 PL PL06840192T patent/PL1968948T3/pl unknown
- 2006-12-12 MY MYPI20082207A patent/MY157733A/en unknown
- 2006-12-12 JP JP2008547679A patent/JP5127723B2/ja active Active
- 2006-12-12 CN CN2011102355739A patent/CN102329270A/zh active Pending
- 2006-12-12 EP EP06840192.6A patent/EP1968948B1/fr active Active
- 2006-12-12 PT PT68401926T patent/PT1968948E/pt unknown
- 2006-12-12 KR KR1020087017543A patent/KR101361460B1/ko active Protection Beyond IP Right Term
- 2006-12-12 SI SI200631619T patent/SI1968948T1/sl unknown
- 2006-12-12 CN CN2006800514795A patent/CN101360718B/zh active Active
- 2006-12-12 ES ES06840192T patent/ES2421746T3/es active Active
- 2006-12-12 NZ NZ569792A patent/NZ569792A/en unknown
- 2006-12-12 CA CA2634149A patent/CA2634149C/fr active Active
- 2006-12-12 BR BRPI0620091-5A patent/BRPI0620091A2/pt not_active Application Discontinuation
- 2006-12-12 AU AU2006330759A patent/AU2006330759B2/en active Active
- 2006-12-20 AR ARP060105662A patent/AR058696A1/es not_active Application Discontinuation
-
2008
- 2008-06-16 IL IL192224A patent/IL192224A/en active IP Right Grant
- 2008-06-30 ZA ZA2008/05705A patent/ZA200805705B/en unknown
- 2008-07-02 EC EC2008008597A patent/ECSP088597A/es unknown
-
2009
- 2009-02-16 HK HK09101437.0A patent/HK1124043A1/xx unknown
-
2012
- 2012-05-03 US US13/463,499 patent/US9156795B2/en active Active
-
2013
- 2013-07-11 HR HRP20130663TT patent/HRP20130663T1/hr unknown
- 2013-07-11 CY CY20131100590T patent/CY1114303T1/el unknown
-
2014
- 2014-01-10 US US14/152,766 patent/US20140221443A1/en not_active Abandoned
-
2015
- 2015-04-28 US US14/698,151 patent/US9562017B2/en active Active
-
2021
- 2021-10-25 HU HUS2100046C patent/HUS2100046I1/hu unknown
- 2021-10-27 NL NL301139C patent/NL301139I2/nl unknown
- 2021-11-05 FR FR21C1051C patent/FR21C1051I2/fr active Active
- 2021-11-26 LT LTPA2021530C patent/LTC1968948I2/lt unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR21C1051I2 (fr) | Nouveau sel hydrogenosulfate | |
NO2021013I1 (no) | filgotinib or a salt thereof | |
LTC2343304I2 (lt) | Biocidiniai boronoftalido junginiai | |
NL300885I2 (nl) | Irinotecansucrosofaatzout | |
ATE458725T1 (de) | Piperazinverbindungen mit herbizider wirkung | |
ATE463485T1 (de) | Piperazinverbindungen mit herbizider wirkung | |
BRPI0816278A2 (pt) | forma sal | |
ATE449085T1 (de) | Piperazinverbindungen mit herbizider wirkung | |
ATE502948T1 (de) | Substituierte bicyclolactamverbindungen | |
DK1919907T5 (da) | Heterocyklisk forbindelse | |
EP2305641A4 (fr) | Composé de sulfonamide ou sel de celui-ci | |
DK1937650T3 (da) | Heterocykliske forbindelser | |
ATE443056T1 (de) | Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen | |
BRPI0807004A2 (pt) | Sal | |
UY3776Q (es) | Reloj pulsera | |
DE602008000563D1 (de) | Angelspule | |
DE602008006282D1 (de) | Angelrolle | |
ZA200800522B (en) | New salt II | |
ATE518827T1 (de) | Aliskiren-nitratsalz | |
SE530154C8 (sv) | Saltblandning | |
FI7694U1 (fi) | Viehe | |
NO346433B1 (no) | Nytt fiskepatogen | |
ATE474459T1 (de) | Angelrute | |
FR2885162B1 (fr) | Nouveau type de volet. | |
ZA200800488B (en) | New Salt III |